Sunzen Biotech Bhd Cash Flow Conversion Efficiency
Sunzen Biotech Bhd cash flow conversion efficiency. Based on the latest financial reports, Sunzen Biotech Bhd (0148) has a cash flow conversion efficiency ratio of 0.027x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (RM3.58 Million ≈ $897.56K USD) by net assets (RM134.42 Million ≈ $33.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Sunzen Biotech Bhd (2016–2023)
Cash flow conversion efficiency of Sunzen Biotech Bhd from 2016 to 2023. This chart illustrates how Sunzen Biotech Bhd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Sunzen Biotech Bhd stock price for real-time trading data and today's change.
Sunzen Biotech Bhd Cash Flow Conversion Ratio Explained
Sunzen Biotech Bhd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sunzen Biotech Bhd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sunzen Biotech Bhd ranked by their cash flow conversion efficiency. Also see Sunzen Biotech Bhd market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kentucky First Federal Bancorp
NASDAQ:KFFB
|
0.018x |
|
K Seng Seng Corporation Bhd
KLSE:5192
|
-0.071x |
|
JC Chemical Co. Ltd
KQ:137950
|
0.093x |
|
Fractal Gaming Group AB
ST:FRACTL
|
0.071x |
|
Joinsoon Electronics MFG Co Ltd
TWO:3322
|
-0.067x |
|
Abcourt Mines Inc.
V:ABI
|
3.298x |
|
PBG S.A
SA:PTBL3
|
0.090x |
|
Krynica Vitamin SA
WAR:KVT
|
0.004x |
Annual Cash Flow Conversion Efficiency for Sunzen Biotech Bhd (2016–2023)
The table below shows the annual cash flow conversion efficiency of Sunzen Biotech Bhd from 2016 to 2023. Review Sunzen Biotech Bhd free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | RM149.84 Million ≈ $37.62 Million |
RM819.39K ≈ $205.72K |
0.005x | +102.08% |
| 2022-12-31 | RM121.88 Million ≈ $30.60 Million |
RM-32.06 Million ≈ $-8.05 Million |
-0.263x | -89.88% |
| 2021-12-31 | RM118.10 Million ≈ $29.65 Million |
RM-16.36 Million ≈ $-4.11 Million |
-0.139x | -268.20% |
| 2020-12-31 | RM87.47 Million ≈ $21.96 Million |
RM7.20 Million ≈ $1.81 Million |
0.082x | +168.12% |
| 2019-12-31 | RM91.37 Million ≈ $22.94 Million |
RM-11.05 Million ≈ $-2.77 Million |
-0.121x | -217.88% |
| 2018-12-31 | RM106.94 Million ≈ $26.85 Million |
RM-4.07 Million ≈ $-1.02 Million |
-0.038x | -194.09% |
| 2017-12-31 | RM99.45 Million ≈ $24.97 Million |
RM4.02 Million ≈ $1.01 Million |
0.040x | +1434.55% |
| 2016-12-31 | RM97.23 Million ≈ $24.41 Million |
RM256.13K ≈ $64.31K |
0.003x | -- |
About Sunzen Biotech Bhd
Sunzen Group Berhad, an investment holding company, engages in the biotechnology research and development, manufacturing, and marketing of animal feed supplement products in Malaysia, China, Singapore, and internationally. It operates through Human Health, Medical Devices and Services, and Loan Financing segments. The company provides veterinary, pharmaceutical, chemical products, animal health, … Read more